As predicted by the decreased affinity to FcγRIIIa, ADCC of Y-443 (L235D) against MDA-MB-231 breast cancer cells was 10-fold lower than its parent antibody, Y-443 (Fig 4). Here, FCGR3A is linked to breast cancer.